About MSP
MSP is a company based in Saint Paul (United States) founded in 1985 was acquired by TSI Incorporated in November 2016. It operates as a Professional Services and Direct-to-Consumer (D2C). MSP has raised $6 million across 2 funding rounds from investors including TSI Incorporated, Hunt Realty Investments and OSTI.GOV. MSP offers products and services including Inhalytix Plus, Turbo II Vaporizer, and PRE Challenge Wafers. MSP operates in a competitive market with competitors including Cytek Biosciences, Accuri Cytometers, ACEA Biosciences, Bioaffinity technologies and NanoFCM, among others.
- Headquarter Saint Paul, United States
-
Sectors
Technology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Msp, A Division Of Tsi Incorporated
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6 M (USD)
in 2 rounds
-
Latest Funding Round
$1.13 M (USD), Grant
Feb 28, 2012
-
Investors
TSI Incorporated
& 2 more
-
Employee Count
Not available
-
Acquired by
TSI Incorporated
(Nov 09, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MSP
MSP offers a comprehensive portfolio of products and services, including Inhalytix Plus, Turbo II Vaporizer, and PRE Challenge Wafers.
Workflows for APSD testing are centralized by Inhalytix Plus.
Vapor delivery for CVD is enhanced by Turbo II.
Wafer cleaning efficiency is validated by PRE Challenge Wafers.
Funding Insights of MSP
MSP has successfully raised a total of $6M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.13 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MSP
MSP has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include TSI Incorporated, Hunt Realty Investments and OSTI.GOV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Hunt Realty Investments is engaged in real estate development and investment management.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Manufacturer of precision measurement instruments and software
|
Locked | Locked | Locked |
Investor details for MSP
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MSP
Investment portfolio details for MSP
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MSP
Detailed financials for MSP
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Msp Comparisons
Peer comparison for MSP
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MSP
MSP operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytek Biosciences, Accuri Cytometers, ACEA Biosciences, Bioaffinity technologies and NanoFCM, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Advanced flow cytometry systems are manufactured for research applications.
|
|
| Locked | Locked | Locked |
Compact flow cytometers for cell analysis are developed and provided.
|
|
| Locked | Locked | Locked |
Instruments for life science research are developed and marketed.
|
|
| Locked | Locked | Locked |
IVD platforms are developed to detect and target cancer cells.
|
|
| Locked | Locked | Locked |
Offers advanced tools for nanoparticle analysis in biotechnology and healthcare.
|
|
| Locked | Locked | Locked |
Instrumentation for cell and protein analysis is developed and marketed.
|
Detailed competitors of MSP
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Msp
Complete news archive for MSP
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MSP
MSP was founded in 1985 and raised its 1st funding round 23 years after it was founded.
MSP is headquartered in Saint Paul, United States. It is registered at Saint Paul, Minnesota, United States.
MSP is a funded company, having raised a total of $6M across 2 funding rounds to date.
Innovative tools for pharmaceutical inhaler testing and semiconductor manufacturing are developed by MSP, a Division of TSI. Focus is placed on aerodynamic particle size distribution, delivered dose uniformity, and in vitro-in vivo correlation in the pharmaceutical sector. In the semiconductor industry, vapor delivery systems for chemical vapor deposition and atomic layer deposition, as well as surface defect inspection tools, are offered. Solutions are tailored to improve process efficiency, product quality, and regulatory compliance across these sectors.
MSP's top competitors include Cytek Biosciences, Bioaffinity technologies and Accuri Cytometers.
MSP offers Inhalytix Plus, Turbo II Vaporizer, and PRE Challenge Wafers.
MSP has 3 investors. Key investors include TSI Incorporated, Hunt Realty Investments, and OSTI.GOV.